Table 2.
Risk of incident dementia in older ESRD patients with secondary hyperparathyroidism (SHPT) comparing those who received treatment during dialysis in our study cohort (A) or only in patients with a diagnosis code of SHPT (B) with those who did not receive treatment, and also comparing treatment by parathyroidectomy compared with cinacalcet (C). Adjusted hazard ratio (aHR) and 95% confidence interval (CI) is reported
| SHPT treatment | Incident rate (cases/100 person-years) | Risk of incident dementia [aHR (95% CI)]a |
|---|---|---|
| A. Entire cohort | ||
| No | 11 | Reference |
| Yes | 6 | 0.58 (0.56–0.59) |
| B. Restricted only to patients with claims diagnosis of SHPT | ||
| No | 10 | Reference |
| Yes | 6 | 0.63 (0.62–0.65) |
| C. Restricted only to patients receiving either treatment | ||
| Cinacalcet | 7.3 | Reference |
| Parathyroidectomy | 6.2 | 0.91 (0.66–1.26) |
Adjusted for age at diagnosis sex, race/ethnicity, employment, geographic region, body mass index, dialysis modality type, primary cause of end-stage renal disease, comorbidities (hypertension, diabetes mellitus, cerebrovascular disease, atherosclerotic heart disease, heart failure, peripheral vascular disease, cancer, functional impairment, alcohol dependence and smoking) and days of previous medication prescription.